Skip to content
MARKETS / NASDAQ / LIVN
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

LivaNova PLC LIVN

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.4B
▲ 10.7% YoY
$-242.5M
▼ 483.5% YoY
$173.3M
▲ 27.5% YoY
In brief

What this company does

LivaNova PLC designs, develops, manufactures, markets and sells medical products, therapies and services. As of December 31, 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries. LivaNova manufactures a majority of its products in facilities located in the U.S., Italy, Germany, Australia and Brazil. It is organized into two reportable segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment designs, develops, manufactures, markets and sells cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems and cannulae, and provides related services. The Neuromodulation segment designs, develops, manufactures, markets and sells devices, including the VNS Therapy System, that deliver neuromodulation therapy for treating DRE and DTD. LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England.

Written from the business description in LivaNova PLC's annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.4B
Revenue, FY2025 · full 12-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.4 · Net income -0.2
0.5B1.0B-0.2B2013201620182020202220242025
Compound annual growth
+10.8%
+8.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−17 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 14.4% · Net -17.5%
10%20%30%-10%-20%-30%2013201620182020202220242025
ROE
FY2025 · ROE -19.2%
10%20%-10%-20%2013201620182020202220242025

Each USD of equity lost 19 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 173.3
80M160M-40M-80M2013201620182020202220242025
Net buybacks $M Dividends $M
FY2020 · Dividends — · Net buybacks 0.0
25.0M50.0M2013201420162017201820192020

Total assetsUSD 2.6B
EquityUSD 1.2B
CashUSD 635.6M
Gross debtUSD 376.1M
Net debtUSD -259.5M
Current ratio1.36×

The company holds more cash than debt.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620142013
Revenue $B1.41.31.21.01.00.91.11.11.01.00.30.3
Operating income $B0.20.1−0.1−0.1−0.0−0.3−0.2−0.20.10.00.10.1
EBITDA $B0.20.2−0.0−0.10.0−0.2−0.1−0.20.10.10.10.1
Income tax $B0.00.0−0.10.00.0−0.0−0.0−0.10.00.00.00.0
Net income $B−0.20.10.0−0.1−0.1−0.3−0.2−0.2−0.0−0.10.10.1
Free cash flow $B0.20.10.00.00.1−0.1−0.10.10.10.10.10.0
EPS, diluted $−4.451.160.32−1.61−2.68−7.18−3.26−3.91−0.52−1.282.172.00
Dividend / sh $············
Payout %············
ROE %−19.24.91.4−6.9−11.3−28.0−11.0−11.4−1.4−3.721.621.2
Shares out B0.050.050.050.050.050.050.050.050.0548.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 2 divergences in 57 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 37 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures2 divergent
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image